Why I Am Still Long Targacept After The Reverse Merger Announcement
Daniel Ward • 12 Comments
Daniel Ward • 12 Comments
Thu, Nov. 3, 8:44 AM
Thu, Aug. 4, 11:00 AM
Thu, Aug. 4, 8:34 AM
Tue, Aug. 2, 9:17 AM
- Gainers: SINO +64%. ESEA +28%. ADXS +25%. TRXC +25%. TOPS +17%. CTRV +17%. CGNX +15%. CBIO +12%. AMKR +12%. SODA +11%. PSTI +10%. VGZ +8%. AVP +8%. KOOL +8%. MNK +7%. GKOS +7%. HZNP +6%. OGEN +6%. OCN +6%. WMB +6%. STX 5%. ROSG 6%. NYRT 5%. INO 5%.
- Losers: IDTI -13%. TXRH -10%. ANGO -9%. GLOP -8%. ALLT -6%.
Thu, Jul. 28, 11:32 AM
- Long-term follow-up data from a 16-subject Phase 1/2 clinical trial assessing Roche's (OTCQX:RHHBY) investigational biologic emicizumab in patients with severe hemophilia A show encouraging safety and prophylactic efficacy regardless of the presence of factor VIII inhibitors. The results were presented at the World Federation of Hemophilia 2016 World Congress in Orlando, FL.
- The data show patients who received once-weekly subcutaneous injections of either 0.3,1.0 or 3.0 mg/kg/week of emicizumab with median follow-up periods of 32.6 months, 27.0 months and 21.4 months, respectively, experienced a sustained decrease of 95% in annualized bleeding rate (ABR), irrespective of their inhibitor status and prior treatment regimen. The ABRs for the three cohorts were 1.4, 0.2 and 0.0, respectively.
- The product candidate's safety profile was consistent with what was previously reported in the Phase 1 study. No thromboembolic (blood clot that breaks loose and clogs another vessel) adverse events or clinically significant laboratory abnormalities were observed.
- Emicizumab is an bispecific antibody engineered to bind to both factors IXa and X, replacing the function of the missing factor VIII, thereby improving clotting function and preventing spontaneous bleeding. It was created by Chugai Pharmaceutical Co. and is being co-developed by Roche. Future clinical trials will explore less frequent dosing schedules.
- Related tickers: (OTC:BIOVF)(NASDAQ:BIIB)(BXLT)(OTCPK:BAYRY)(NASDAQ:OPK)(NYSE:SNY)(NASDAQ:ALNY)(NASDAQ:SGMO)(NASDAQ:CBIO)(NASDAQ:BMRN)
Tue, Jul. 26, 12:48 PM
Tue, Jun. 21, 11:16 AM
- Thinly traded nano cap MYOS RENS (MYOS +12.2%) heads north on a 6x surge in volume, albeit on turnover of only 79K shares, adding to yesterday's 26% move on 19x higher volume. No particular news accounts for the action, but some other tiny firms have shown similar price action lately, some explained, some not.
- MYOS RENS develops and commercializes biotherapeutic and bionutritional products that improve muscle mass. Its lead product is a nutritional supplement called Fortetropin, a protein/lipid complex consisting of ~250 proteins, ~50 lipids, a range of peptides and other unnamed molecules isolated from egg yolks.
- Recent bullish price action: (PULM -9.1%)(BLPH -7.7%)(IMNP +35%)(JAGX +1.4%)(BSPM -12.1%)(CYCC +6.3%)(CBIO -6.2%)(GBIM -5.3%)
Thu, Jun. 16, 12:02 PM
- Thinly traded nano cap Pulmatrix (PULM +31.9%) jumps on a whopping 47x surge in volume, albeit on turnover of 992K shares. The stock is up almost 70% since Tuesday. No particular news accounts for the bullish behavior, although other small biotechs are experiencing similar action.
- The company has three product candidates in its pipeline, none further than Phase 1. Last month, it announced that it had completed dosing in healthy volunteers in a Phase 1 pharmacokinetic study of PUR0200, its candidate for the treatment of bronchospasm in patients with chronic obstructive pulmonary disease (COPD), with the aim of showing bioequivalence with a currently approved product.
- Other pipeline programs are PUR1900 for cystic fibrosis and PUR1500 for ideopathic pulmonary fibrosis.
- Tickers showing recent price spikes (some explained, some not): (BLPH -1.9%)(IMNP -6%)(JAGX -5.8%)(BSPM +9.2%)(CYCC -7.6%)(CBIO)(GBIM +30.5%)
Wed, Jun. 15, 11:00 AM
Mon, Jun. 13, 11:45 AM
Fri, May 27, 12:45 PM
Thu, May 26, 5:09 PM
- The FDA approves CSL Behring's AFSTYLA [Antihemophilic Factor (Recombinant) Single Chain], its long-acting recombinant factor VIII single-chain therapy for the treatment of adults and children with hemophilia A.
- AFSTYLA is indicated for routine prophylaxis to reduce the frequency of bleeding episodes with dosing of two-to-three times per week, on-demand treatment and control of bleeding episodes and the perioperative management of bleeding.
- Market launch will commence this summer.
- Hemophilia A-related tickers: (NYSE:BXLT)(OTCPK:BAYRY)(NASDAQ:BMRN)(NYSE:OPK)(NYSE:SNY)(NASDAQ:ALNY)(NASDAQ:BIIB)(NASDAQ:SGMO)(OTCQX:RHHBY)(NASDAQ:CBIO)
Wed, May 11, 12:49 PM
Dec. 29, 2015, 12:45 PM
Oct. 16, 2015, 12:45 PM
Sep. 17, 2015, 12:41 PM